| Dr Michael John Papamichael, MD | |
|
4401 Francis Lewis Blvd, Bayside, NY 11361-3028 | |
| (718) 717-0280 | |
| (718) 717-0286 |
| Full Name | Dr Michael John Papamichael |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Experience | 30 Years |
| Location | 4401 Francis Lewis Blvd, Bayside, New York |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003997438 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | 2083541 (New York) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| New York University Langone Medical Center | New york, NY | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| New York University | 1355232422 | 4431 |
News Archive
Bedford Laboratories™, a division of Ben Venue Laboratories, Inc., is pleased to announce the addition of Dactinomycin for Injection USP 500 mcg (0.5 mg) to its comprehensive line of generic oncology products. Dactinomycin was approved earlier this year by the U.S. Food and Drug Administration (FDA) and is AP rated and equivalent to Cosmegen® by Lundbeck Inc. Each single dose vial contains 0.5 mg (500mcg) of dactinomycin and 20 mg of mannitol and is individually boxed.
A team of Neuroscientists from NeuroCure Cluster of Excellence at Charité - Universitätsmedizin Berlin and Baylor College of Medicine in Houston, Texas, have made a major breakthrough in understanding how signals are processed in the human brain.
VivaPhi and the Center of Health Engagement announce their strategic partnership to define and deliver a networked, learning, and value-based health system. The partnership will engage in research using health data to develop insights into how health care decisions are made in by patients, and how those decisions influence new models of care.
Nanosphere, Inc., a leader in the development and commercialization of advanced molecular diagnostics systems, today reported financial results for the first quarter ended March 31, 2010.
› Verified 2 days ago
| Entity Name | New York University |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1285826438 PECOS PAC ID: 1355232422 Enrollment ID: O20081202000185 |
News Archive
Bedford Laboratories™, a division of Ben Venue Laboratories, Inc., is pleased to announce the addition of Dactinomycin for Injection USP 500 mcg (0.5 mg) to its comprehensive line of generic oncology products. Dactinomycin was approved earlier this year by the U.S. Food and Drug Administration (FDA) and is AP rated and equivalent to Cosmegen® by Lundbeck Inc. Each single dose vial contains 0.5 mg (500mcg) of dactinomycin and 20 mg of mannitol and is individually boxed.
A team of Neuroscientists from NeuroCure Cluster of Excellence at Charité - Universitätsmedizin Berlin and Baylor College of Medicine in Houston, Texas, have made a major breakthrough in understanding how signals are processed in the human brain.
VivaPhi and the Center of Health Engagement announce their strategic partnership to define and deliver a networked, learning, and value-based health system. The partnership will engage in research using health data to develop insights into how health care decisions are made in by patients, and how those decisions influence new models of care.
Nanosphere, Inc., a leader in the development and commercialization of advanced molecular diagnostics systems, today reported financial results for the first quarter ended March 31, 2010.
› Verified 2 days ago
| Entity Name | New York University |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1285826438 PECOS PAC ID: 1355232422 Enrollment ID: O20090822000026 |
News Archive
Bedford Laboratories™, a division of Ben Venue Laboratories, Inc., is pleased to announce the addition of Dactinomycin for Injection USP 500 mcg (0.5 mg) to its comprehensive line of generic oncology products. Dactinomycin was approved earlier this year by the U.S. Food and Drug Administration (FDA) and is AP rated and equivalent to Cosmegen® by Lundbeck Inc. Each single dose vial contains 0.5 mg (500mcg) of dactinomycin and 20 mg of mannitol and is individually boxed.
A team of Neuroscientists from NeuroCure Cluster of Excellence at Charité - Universitätsmedizin Berlin and Baylor College of Medicine in Houston, Texas, have made a major breakthrough in understanding how signals are processed in the human brain.
VivaPhi and the Center of Health Engagement announce their strategic partnership to define and deliver a networked, learning, and value-based health system. The partnership will engage in research using health data to develop insights into how health care decisions are made in by patients, and how those decisions influence new models of care.
Nanosphere, Inc., a leader in the development and commercialization of advanced molecular diagnostics systems, today reported financial results for the first quarter ended March 31, 2010.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Michael John Papamichael, MD 4401 Francis Lewis Blvd, Bayside, NY 11361-3028 Ph: (718) 717-0280 | Dr Michael John Papamichael, MD 4401 Francis Lewis Blvd, Bayside, NY 11361-3028 Ph: (718) 717-0280 |
News Archive
Bedford Laboratories™, a division of Ben Venue Laboratories, Inc., is pleased to announce the addition of Dactinomycin for Injection USP 500 mcg (0.5 mg) to its comprehensive line of generic oncology products. Dactinomycin was approved earlier this year by the U.S. Food and Drug Administration (FDA) and is AP rated and equivalent to Cosmegen® by Lundbeck Inc. Each single dose vial contains 0.5 mg (500mcg) of dactinomycin and 20 mg of mannitol and is individually boxed.
A team of Neuroscientists from NeuroCure Cluster of Excellence at Charité - Universitätsmedizin Berlin and Baylor College of Medicine in Houston, Texas, have made a major breakthrough in understanding how signals are processed in the human brain.
VivaPhi and the Center of Health Engagement announce their strategic partnership to define and deliver a networked, learning, and value-based health system. The partnership will engage in research using health data to develop insights into how health care decisions are made in by patients, and how those decisions influence new models of care.
Nanosphere, Inc., a leader in the development and commercialization of advanced molecular diagnostics systems, today reported financial results for the first quarter ended March 31, 2010.
› Verified 2 days ago
Saffa Ahmad, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 4402 Francis Lewis Blvd, Bayside, NY 11361 Phone: 718-631-0500 | |
Mohamed Mansour, Internal Medicine Medicare: Medicare Enrolled Practice Location: 2912 210th Pl, Bayside, NY 11360 Phone: 718-773-2011 Fax: 718-773-3728 | |
Svetlana Fuzaylova, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 4402 Francis Lewis Blvd, Suite A, Bayside, NY 11361 Phone: 718-631-0500 Fax: 718-281-1276 | |
Miss Niyati N. Trivedi, M.D. Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 21435 42nd Ave, 3rd Floor, Bayside, NY 11361 Phone: 718-229-4868 | |
John Joachim Rawlings, MD Internal Medicine Medicare: Medicare Enrolled Practice Location: 4402 Francis Lewis Blvd, Suite A, Bayside, NY 11361 Phone: 718-631-0500 Fax: 718-281-1276 | |
Elina Yushuvayev, MD Internal Medicine Medicare: May Accept Medicare Assignments Practice Location: 22215 Northern Blvd Lbby A, Bayside, NY 11361 Phone: 718-215-0020 Fax: 616-226-4785 |